Sec. 3. Interagency research on health impacts of indoor residential mold
304 words·~1 min read·
/bill/118/hr/5533/ih/section-3·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
As soon as practicable after the date of enactment of this Act, the Director of the National Institute of Environmental Health Sciences at the National Institutes of Health, in conjunction with the Secretary of Housing and Urban Development, the Director of the Centers for Disease Control and Prevention, the Administrator of the Environmental Protection Agency, the Secretary of Energy, the Secretary of Health and Human Services, the President of the National Academy of Sciences, and the Chair of the board of directors of the National Institute of Building Sciences shall jointly conduct a comprehensive study of the health effects of indoor residential mold growth, using the most up-to-date scientific peer-reviewed medical literature.
The study conducted under paragraph
(1)shall ascertain, among other things— detailed information about harmful or toxigenic mold, as well as any toxin or toxic compound such mold can produce; the most accurate research-based methods of detecting harmful or toxigenic mold; potential dangers of prolonged or chronic exposure to indoor residential mold growth; the hazards involved with inadequate residential mold inspections and improper indoor residential mold remediation; the estimated current public health burden of new or exacerbated physical illness resulting from exposure to indoor residential mold, including its disproportionate impact on vulnerable communities, including children and seniors; improved understanding of the different health symptomology that can result from exposure to mold in indoor residential environments; ongoing surveillance of the prevalence of idiopathic pulmonary hemorrhage
(AIPH)in infants; and longitudinal studies on the effects of indoor old exposure in early childhood on the development of asthma and other respiratory illnesses. Not later than the expiration of the 3-year period beginning on the date of the enactment of this Act, the results of the study conducted under paragraph
(1)shall be submitted to Congress and the President and made available to the general public.